Investing.com - Mesoblast reported on Tuesday first quarter earnings that beat analysts' forecasts and revenue that fell short of expectations.
Mesoblast announced earnings per share of $-0.122 on revenue of $1.5M. Analysts polled by Investing.com anticipated EPS of $-0.150 on revenue of $3.47M.
Mesoblast shares are down 32.29% from the beginning of the year and are trading at $3.250 , down-from-52-week-high.
Mesoblast follows other major Healthcare sector earnings this month
Mesoblast's report follows an earnings beat by Eli Lilly on Tuesday, November 1, 2022, who reported EPS of $1.98 on revenue of $6.94B, compared to forecasts EPS of $1.91 on revenue of $6.91B.
AbbVie had beat expectations on Friday, October 28, 2022 with third quarter EPS of $3.66 on revenue of $14.81B, compared to forecast for EPS of $3.58 on revenue of $14.93B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar